Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.

Abstract

BACKGROUND:

Due to prophylactic colectomy, mortality in patients with familial adenomatous polyposis (FAP) has changed, with duodenal cancer currently being the main cause of death. Although celecoxib reduces duodenal polyp density in patients with FAP, its long-term use may increase the risk of cardiovascular events and alternatives need to be explored. Preclinical studies suggest that the combination of celecoxib with ursodeoxycholic acid (UDCA) is a potentially effective strategy. We performed a randomized, double-blind, placebo-controlled trial to investigate the effect of celecoxib and UDCA co-treatment on duodenal adenomatosis in patients with FAP.

METHODS:

Patients with FAP received celecoxib (400 mg twice daily) and UDCA (1000-2000 mg daily, ~20-30 mg/kg/day, n=19) or celecoxib and placebo (n=18) orally for 6 months. Primary outcome was drug efficacy, assessed by comparing duodenal polyp density at pre- and post-intervention by blinded review of endoscopic recordings. As secondary outcomes, cell proliferation, apoptosis, and COX-2 levels in normal duodenal mucosa were assessed by immunohistochemistry or real-time quantitative polymerase chain reaction.

RESULTS:

In intention-to-treat analysis, deceased polyp density was observed after celecoxib/placebo treatment (p=0.029), whereas increased polyp density was observed after celecoxib/UDCA treatment (p=0.014). The difference in change in duodenal polyp density was statistically significant between the groups (p=0.011). No changes in secondary outcomes were observed. Thirty patients (81%) reported one or more adverse events, 16 patients (84%, Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE) grade 1-3) treated with celecoxib/UDCA and 14 patients (78%, CTCAE grade 1-2) treated with celecoxib/placebo. Nine patients (24%) discontinued intervention prematurely, 5 patients (26%) treated with celecoxib/UDCA and 4 patients (22%) treated with celecoxib/placebo.

CONCLUSIONS:

Celecoxib reduces duodenal polyp density in patients with FAP, and unexpectedly, high dose UDCA co-treatment counteracts this effect. The benefit of long term use of celecoxib for duodenal cancer prevention needs to be weighed against the (risk of) adverse events.

TRIAL REGISTRATION:

http://ClinicalTrials.gov, identifier NCT00808743.

• Authors: Bjorn W H van Heumen, Hennie M J Roelofs, M Elisa Vink-Börger, Evelien Dekker, Elisabeth M H Mathus-Vliegen, Jan Dees, Jan J Koornstra, Alexandra M J Langers, Iris D Nagtegaal, Ellen Kampman, Wilbert H M Peters, Fokko M Nagengast
• Journal: Orphanet journal of rare diseases (Orphanet J Rare Dis) Vol. 8 Pg. 118 (Aug 06 2013) ISSN: 1750-1172 [Electronic] England
• PMID: 23919274 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Cholagogues and Choleretics
• Cyclooxygenase 2 Inhibitors
• Pyrazoles
• Sulfonamides
• Ursodeoxycholic Acid
• Celecoxib

Topics

• Adenomatous Polyposis Coli (drug therapy, pathology)
• Adolescent
• Adult
• Aged
• Celecoxib
• Cholagogues and Choleretics (therapeutic use)
• Cyclooxygenase 2 Inhibitors (therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Duodenum (pathology)
• Female
• Humans
• Intestinal Polyps (drug therapy, pathology)
• Male
• Middle Aged
• Pyrazoles (therapeutic use)
• Sulfonamides (therapeutic use)
• Treatment Outcome
• Ursodeoxycholic Acid (therapeutic use)
• Young Adult